Category Archives: "News"

MRI in Multiple Sclerosis Guidelines Update: North America, Europe align on new recommendations
These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more [...]
Congratulations to Dr. Robert Lisak: recipient of ANA’s Distinguished Neurology Teacher Award
The CMSC Board, staff, and members would like to congratulate Dr. Robert Lisak for his selection as a recipient of the 2021 Distinguished [...]
Study on cognitive processing speed changes in RMS subjects treated with Ozanimod
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
#MSVisibility virtual concert: recording now available
#MSVisibility Virtual Concert Thank you for your interest in the first-ever #MSVisibility Virtual Concert, a free event to celebrate and [...]
Phase 1/2 study to evaluate the safety and efficacy of ATA188 in progressive multiple sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the [...]
New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Janssen announces U.S. FDA approval of PONVORYâ„¢ (ponesimod)
Head-to-head pivotal clinical trial results showed PONVORYâ„¢ treatment led to nearly a third fewer annual relapses than [...]
NeurologyLive® & the CMSC launches MS Cure Connections® Video Series
A diverse panel including an expert neurologist, a psychologist, a patient, and a care partner discuss the patient's journey with [...]
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
Please be advised  of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM